These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1371 related articles for article (PubMed ID: 9235724)
1. [Prevention and treatment of febrile neutropenia]. Montemurro F; Gallicchio M; Aglietta M Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724 [TBL] [Abstract][Full Text] [Related]
2. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696 [TBL] [Abstract][Full Text] [Related]
3. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939 [TBL] [Abstract][Full Text] [Related]
4. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560 [TBL] [Abstract][Full Text] [Related]
5. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy. Wong SF; Chan HO Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284 [TBL] [Abstract][Full Text] [Related]
6. Colony-stimulating factors for the management of neutropenia in cancer patients. Dale DC Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591 [TBL] [Abstract][Full Text] [Related]
7. The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer. Liang DC Paediatr Drugs; 2003; 5(10):673-84. PubMed ID: 14510625 [TBL] [Abstract][Full Text] [Related]
8. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): an appraisal of its pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplant. Goa KL; Bryson HM Pharmacoeconomics; 1994 Jan; 5(1):56-77. PubMed ID: 10146867 [TBL] [Abstract][Full Text] [Related]
9. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Moen MD; Lyseng-Williamson KA; Scott LJ Drugs; 2009; 69(3):361-92. PubMed ID: 19275278 [TBL] [Abstract][Full Text] [Related]
10. Lack of benefit of granulocyte macrophage or granulocyte colony stimulating factor in patients with febrile neutropenia. Siddiqui T; Burney IA; Kakepoto GN; Khurshid M; Salam A; Smego RA J Pak Med Assoc; 2002 May; 52(5):206-10. PubMed ID: 12174492 [TBL] [Abstract][Full Text] [Related]
11. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. García-Carbonero R; Mayordomo JI; Tornamira MV; López-Brea M; Rueda A; Guillem V; Arcediano A; Yubero A; Ribera F; Gómez C; Trés A; Pérez-Gracia JL; Lumbreras C; Hornedo J; Cortés-Funes H; Paz-Ares L J Natl Cancer Inst; 2001 Jan; 93(1):31-8. PubMed ID: 11136839 [TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group. Ozkaynak MF; Krailo M; Chen Z; Feusner J Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544 [TBL] [Abstract][Full Text] [Related]